Based on both histological and serological results, patients were categorised into a low-risk or high-risk group. Low risk was defined as AG/IM limited to antrum and normal biomarkers (no Helicobacter pylori, normal PGI/PGII and G-17 levels). High-risk group was defined as AG/IM in both antrum and corpus and/or abnormal biomarkers.

Mean follow-up time was 50.8 months (SD 32). Missing n=68 (including one gastric cancer case), as only patients who underwent at least two surveillance endoscopies during follow-up were included.

AG, atrophic pangastritis; HDG, high-grade adenoma/dysplasia; IM, intestinal metaplasia; G-17, gastrin-17; PGI, pepsinogen I; PGII, pepsinogen II.